康希諾(06185.HK)逆彈4.5%曾高見238元 重組新冠疫苗獲軍隊特需藥品批件
康希諾生物(06185.HK)公布重組新冠疫苗獲軍隊特需藥品批件,該股今早逆市曾漲逾8%高見238元,創逾一個月高遇壓,曾回順至222.8元,現造229.8元,逆升4.5%,成交55萬股。
康希諾公布,公司與軍事科學院軍事醫學研究院生物工程研究所聯合開發的重組新型冠狀病毒疫苗Ad5-nCoV,已於6月25日獲得中央軍委後勤保障部衛生局頒發的軍隊特需藥品批件,有效期一年。Ad5-nCoV的I期及II期臨床試驗已在內地開展,總體試驗結果表明,Ad5-nCoV具有預防由SARS-CoV-2引起的疾病潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.